Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Prostate cancer highlights at ASCO GU 2025: TALAPRO-2 & EZH2 inhibitors

Omid Yazdanpanah • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer Enzalutamide Talazoparib
TALAPRO-2

Omid Yazdanpanah, MD, University of California, Irvine, CA, gives an overview of recent updates in prostate cancer at ASCO GU 2025, including findings from the TALAPRO-2 trial (NCT03395197) of first-line talazoparib and enzalutamide in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr Yazdanpanah additionally touches on novel EZH2 inhibitors. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Omid Yazdanpanah

VISION: secondary analysis of 177Lu-PSMA-617 and ARPIs in mCRPC
2:25
VISION: secondary analysis of 177Lu-PSMA-617 and ARPIs in mCRPC
Omid Yazdanpanah • 14 Feb 2025
ENZA-p: OS and QoL of 177Lu-PSMA-617 and enzalutamide in mCRPC
0:46
ENZA-p: OS and QoL of 177Lu-PSMA-617 and enzalutamide in mCRPC
Omid Yazdanpanah • 14 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals